Skip to main content
Explore URMC
menu

Cohort Discovery

The UR CTSI now offers two different intuitive, user-friendly, HIPAA-compliant cohort discovery tools to help researchers determine study feasibility, obtain summary patient counts, and identify sites for potential partnerships in multi-site studies: TriNetX and the ACT Network. Both offer a myriad of benefits:

  • Real-time, open-access, HIPAA-compliant platforms that provide de-identified summary patient data
  • Use for study feasibility, which does not require RSRB approval
  • Online self-service with free training and closed captionining available

 

 

TriNetX

Query local EMR data and get secure, de-identified summary patient counts to determine the feasibility of your clinical studies.

 

ACT Network

 Validate study feasibility using aggregated EMR data from across the nation and identify potential partner sites for multi-site studies.

 

FAQ

Find answers to frequently asked questions about navigating and using TriNetX and ACT, as well as troubleshooting issues.  

Which tool is right for you?

  • I need to identify the number of UR Medicine patients with a particular set of clinical criteria.
    • Use TriNetX
      • URMC has enough patients to satisfy my sample size criteria.
        • Coming soon: TriNetX will soon have more analytics capabilities.
      • URMC does not have enough patients to satisfy my sample size.
        • Consider running a multi-site clinical study.
          • Use ACT to identify potential collaborating sites with additional patients meeting study criteria.

Questions? Email CTSI_Informatics@urmc.rochester.edu